January 2012/NutraSolutions -- The market for probiotics is growing in response to impressive consumer interest. According to Business Insights, the U.S. market grew 8.7% between 2003-2008 to $5 billion, and it is expected to grow at 5% through 2013 to a value of $6.4 billion.
Many probiotic organisms are sensitive to normal physiological conditions, such as the low pH of the stomach and exposure to bile salts in the gastrointestinal tract. Viability may also be affected by manufacturing processes, storage and shipping conditions. Refrigeration is required to achieve acceptable shelflife, which limits formulation.


Patented GanedenBC30 (Bacillus coagulans GBI-30, 6086) is a unique bacterial cell, due to its ability to form a protective spore which safeguards the cell from the heat and pressure of manufacturing processes; challenges of shelflife; and the acid and bile in the digestive system. Once in the small intestine, the viable spore is able to germinate and produce new vegetative cells or “good” bacteria.
The spore-forming nature of GanedenBC30 provides excellent stability, requires no refrigeration and can be formulated into products with shelflives of two years and longer. It can withstand high-temperature processes (such as baking and boiling), low-temperature processes (such as freezing and refrigeration) and high-pressure applications, like extrusion and roll-forming. GanedenBC30 is self-affirmed GRAS and kosher-certified.
Studies have shown GanedenBC30 helps support the immune and digestive systems. For example, one study showed consumption of 2 billion CFUs of the bacterium per day for 30 days led to a significant increase in T-cell response to certain viral respiratory tract infections1. Further, in a study of 10 healthy subjects, it significantly influenced CD3(+)CD69(+) cells, IL-6, IL-8, interferon-gamma (IFN-gamma), TNF-a and IL-1beta levels, following the same dose over 28 days2
 Another study conducted over 60 days on 45 patients with rheumatoid arthritis found GanedenBC30 supplementation, compared to a placebo, provided improvement in pain mitigation; the ability to participate in daily activities and a reduction in the inflammatory marker C-reactive protein3.
An additional study performed with 52 subjects with diarrhea-predominant irritable bowel disease who received GanedenBC30, found the average number of daily bowel movements was significantly reduced compared to placebo4. Additionally, supplementation with the bacterium resulted in significantly lower abdominal pain and distension in 61 adults with post-prandial, intestinal gas-related symptoms (abdominal pain, distention, flatulence)5.
With its unique spore-forming characteristics and strong scientific support, GanedenBC30 represents an interesting delivery system for probiotics for a wide range of food and beverages. NS

1 Baron, M. 2009. Postgrad Med. 121(2):114-8.
2 Kimmel M, et al. 2010.  Meth. Find Exp. Clin. Pharmacol. 32(2):129-32.
3 Mandel, DR, et al. 2010. BMC Comp. Alter.  Med. 10:1.
4 Dolin, BJ. 2009. Methods Find Exp Clin Pharmacol. 31(10): 655–659.
5 Kalman, DS, et al. 2009. BMC Gastroenterol. 9:85.

For more information:
Ganeden Biotech • Mayfield Heights, Ohio
440-229-5200 • www.ganedenlabs.com